Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07215468) titled 'HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study' on Oct. 9.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: TaiMed Biologics Inc.

Condition: HIV -1 Infection

Intervention: Drug: TMB-365 Drug: TMB-380

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 2025

Target Sample Size: 75

To know more, visit https://clinicaltrials.gov/study/NCT07215468

Published by HT Digital Content Services with permission from Health Daily Di...